Malaria treatment and prophylaxis in endemic and nonendemic countries: Evidence on strategies and their cost-effectiveness

Future Microbiology

Volumn 6, Issue 12, 2011, Pages 1485-1500

  Van Vugt, Michle ^a   Van Beest, Anne ^b   Sicuri, Elisa ^c   Van Tulder, Maurits ^b   Grobusch, Martin P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

ACTs; Availability and accurate use of diagnostic malaria methods; Cost effectiveness; Malaria chemoprophylaxis in travelers n malaria prophylaxis; Malaria treatment

Indexed keywords

AMODIAQUINE; AMODIAQUINE PLUS ARTESUNATE; ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE; CHLOROQUINE; INSECT REPELLENT; MEFLOQUINE; PYRIMETHAMINE PLUS SULFADOXINE; QUININE;

ANTIMICROBIAL THERAPY; BED NET; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DRUG COST; DRUG INDICATION; DRUG INTERMITTENT THERAPY; HUMAN; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MICROSCOPY; PARASITE IDENTIFICATION; PARASITE TRANSMISSION; PATIENT REFERRAL; PLASMODIUM VIVAX MALARIA; PREGNANT WOMAN; PRIORITY JOURNAL; RAPID DIAGNOSTIC TEST; REVIEW; SYSTEMATIC REVIEW; TRAVEL;

ANTIMALARIALS; CHEMOPREVENTION; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; ENDEMIC DISEASES; FEMALE; HUMANS; MALARIA; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 82455172104     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.11.138     Document Type: Review

References (59)

1. Davis WA, Clarke PM, Siba PM et al. Cost-effectiveness of artemisinin combination therapy for uncomplicated malaria in children: data from Papua New Guinea. Bull. World Health Organ. 89(3), 211-220 (2011).
2. Buchanan J, Mihaylova B, Gray A, White N. Cost-effectiveness of pre-referral antimalarial, antibacterial, and combined rectal formulations for severe febrile illness. PLoS ONE 5(12), e14446 (2010).
3. Grobusch MP, Kremsner PG. Uncomplicated malaria. Curr. Trop. Microbiol. Immunol. 295, 83-104 (2005).
4. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst. Rev. 3, CD007483 (2009).
5. Chanda P, Castillo-Riquelme M, Masiye F. Cost-effectiveness analysis of the available strategies for diagnosing malaria in outpatient clinics in Zambia. Cost Eff. Resour. Alloc. 7, 5 (2009).
6. Rolland E, Checchi F, Pinoges L, Balkan S, Guthmann JP, Guerin PJ. Operational response to malaria epidemics: are rapid diagnostic tests cost-effective? Trop. Med. Int. Health 11(4), 398-408 (2006).
7. Ly AB, Tall A, Perry R et al. Use of HRP-2-based rapid diagnostic test for Plasmodium falciparum malaria: assessing accuracy and cost-effectiveness in the villages of Dielmo and Ndiop, Senegal. Malar. J. 9, 153 (2010).
8. Gallup JL, Sachs JD. The economic burden of malaria. Am. J. Trop. Med. Hyg. 64(Suppl. 1-2), 85-96 (2001).
9. Sachs J, Malaney P. The economic and social burden of malaria. Nature 415(6872), 680-685 (2002).
10. Chanda P, Masiye F, Chitah BM et al. A cost-effectiveness analysis of artemether lumefantrine for treatment of uncomplicated malaria in Zambia. Malar. J. 6, 21 (2007).
11. Price R, Nosten F, Simpson JA et al. Risk factors for gametocyte carriage in uncomplicated falciparum malaria. Am. J. Trop. Med. Hyg. 60(6), 1019-1023 (1999).
12. Targett G, Drakeley C, Jawara M et al. Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. J. Infect. Dis. 183(8), 1254-1259 (2001).
13. Giha HA. Artemisinin derivatives for treatment of uncomplicated Plasmodium falciparum malaria in Sudan: too early for too much hope. Parasitol. Res. 106(3), 549-552 (2010).
14. Lubell Y, Reyburn H, Mbakilwa H et al. The Cost-effectiveness of parasitologic diagnosis for malaria-suspected patients in an era of combination therapy. Am. J. Trop. Med. Hyg. 77(Suppl. 6), 128-132 (2007).
15. Dondorp AM, Fanello CI, Hendriksen IC et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 13, 376(9753), 1647-1657 (2010).
16. Jones KL, Donegan S, Lalloo DG. Artesunate versus quinine for treating severe malaria. Cochrane Database Syst. Rev. 4, CD005967 (2007).
17. Lubell Y, Yeung S, Dondorp AM et al. Cost-effectiveness of artesunate for the treatment of Severe malaria. Trop. Med. Int. Health 14(3), 332-337 (2009).
18. Gomes MF, Faiz MA, Gyapong JO et al. Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. Lancet. 14, 373(9663), 557-566 (2009).
19. Tozan Y, Klein EY, Darley S, Panicker R, Laxminarayan R, Breman JG. Prereferral rectal artesunate for treatment of severe childhood malaria: a cost-effectiveness analysis. Lancet 4, 376(9756), 1910-1915 (2010).
20. Grobusch MP. Early rectal artesunate administration: a life-saver in remote areas? Future Microbiol. 4(4), 397-400 (2009).
21. Conteh L, Sicuri E, Manzi F et al. The cost-effectiveness of intermittent preventive treatment for malaria in infants in sub-Saharan Africa. PLoS ONE 5(6), e10313 (2010).
22. Hutton G, Schellenberg D, Tediosi F et al. Cost-effectiveness of malaria intermittent preventive treatment in infants (IPTi) in Mozambique and the United Republic of Tanzania. Bull. World Health Organ. 87(2), 123-129 (2009).
23. Conteh L, Patouillard E, Kweku M, Legood R, Greenwood B, Chandramohan D. Cost effectiveness of seasonal intermittent preventive treatment using amodiaquine & artesunate or sulphadoxine-pyrimethamine in Ghanaian children. PLoS ONE 5(8), e12223 (2010).
24. Wilson AL; IPTc Taskforce. A systematic review and meta-analysis of the efficacy and safety of intermittent preventive treatment of malaria in children (IPTc). PLoS ONE 6(2), e16976 (2011).
25. Bojang KA, Akor F, Conteh L et al. Two strategies for the delivery of IPTc in an area of seasonal malaria transmission in the Gambia: a randomised controlled trial. PLoS Med. 8(2), e1000409 (2011).
26. Lubell Y, Mills AJ, Whitty CJ, Staedke SG. An economic evaluation of home management of malaria in Uganda: an interactive Markov model. PLoS ONE 5(8), e12439 (2010).
27. Rodriguez-Morales AJ, Ferrer MV, Barrera MA, Pacheco M, Daza V, Franco-Paredes C. Imported cases of malaria admitted to two hospitals of Margarita Island, Venezuela, 1998-2005. Travel Med. Infect. Dis. 7(1), 44-48 (2009).
28. Zoller T, Naucke TJ, May J et al. Malaria transmission in non-endemic areas: case report, review of the literature and implications for public health management. Malar. J. 8, 71 (2009).
29. Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria. Int. J. Technol. Assess. Health. Care 21(2), 240-245 (2005).
30. Shillcutt S, Morel C, Goodman C et al. Cost-effectiveness of malaria diagnostic methods in sub-Saharan Africa in an era of combination therapy. Bull. World Health Organ. 86(2), 101-110 (2008).
31. Sicuri E, Bardaji A, Nhampossa T et al. Cost-effectiveness of intermittent preventive treatment of malaria in pregnancy in southern Mozambique. PLoS ONE 5(10), e13407 (2010).
32. Jamison DT, Breman JG, Measham AR et al. Disease Control Priorities in Developing Countries. Oxford University Press, Oxford, UK (1993).
33. Mosha JF, Conteh L, Tediosi F et al. Cost implications of improving malaria diagnosis: findings from north-eastern Tanzania. PLoS ONE 5(1), e8707 (2010).
34. Lubell Y, Reyburn H, Mbakilwa H et al. The impact of response to the results of diagnostic tests for malaria: cost-benefit analysis. BMJ 336(7637), 202-205 (2008).
35. Lubell Y, Hopkins H, Whitty CJ, Staedke SG, Mills A. An interactive model for the assessment of the economic costs and benefits of different rapid diagnostic tests for malaria. Malar. J. 7, 21 (2008).
36. Zikusooka CM, McIntyre D, Barnes KI. Should countries implementing an artemisinin-based combination malaria treatment policy also introduce rapid diagnostic tests? Malar. J. 7, 176 (2008).
37. Uzochukwu BS, Obikeze EN, Onwujekwe OE, Onoka CA, Griffiths UK. Cost-effectiveness analysis of rapid diagnostic test, microscopy and syndromic approach in the diagnosis of malaria in Nigeria: implications for scaling-up deployment of ACT. Malar. J. 8, 265 (2009).
38. Wiseman V, Kim M, Mutabingwa TK, Whitty CJ. Cost-effectiveness study of three antimalarial drug combinations in Tanzania. PLoS Med. 3(10), e373 (2006).
39. Coleman PG, Morel C, Shillcutt S, Goodman C, Mills AJ. A threshold analysis of the cost-effectiveness of artemisinin-based combination therapies in sub-saharan Africa. Am. J. Trop. Med. Hyg. 71(Suppl. 2), 196-204 (2004).
40. de Oliveira MR, de Castro GA, Toscano CM. Cost effectiveness of OptiMal(R) rapid diagnostic test for malaria in remote areas of the Amazon Region, Brazil. Malar. J. 9, 277 (2010).
41. Rosas Aguirre AM, Llanos Zavalaga LF, Trelles de BM. Cost-effectiveness ratio of using rapid tests for malaria diagnosis in the Peruvian Amazon. Rev. Panam. Salud. Publica. 25(5), 377-388 (2009).
42. Lemma H, San SM, Lofgren C, Barnabas G. Cost-effectiveness of three malaria treatment strategies in rural Tigray, Ethiopia where both Plasmodium falciparum and Plasmodium vivax co-dominate. Cost Eff. Resour. Alloc. 9, 2 (2011).
43. Lubell Y, Riewpaiboon A, Dondorp AM, et al.Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa. Bull. World Health Organ. 89(7), 504-512. (2011)
44. Mbonye AK, Hansen KS, Bygbjerg IC, Magnussen P. Intermittent preventive treatment of malaria in pregnancy: the incremental cost-effectiveness of a new delivery system in Uganda. Trans. R. Soc. Trop. Med. Hyg. 102(7), 685-693 (2008).
45. Temperley M, Mueller DH, Njagi JK et al. Costs and cost-effectiveness of delivering intermittent preventive treatment through schools in western Kenya. Malar. J. 7, 196 (2008).
46. Clarke SE, Jukes MC, Njagi JK et al. Effect of intermittent preventive treatment of malaria on health and education in schoolchildren: a cluster-randomised, double-blind, placebo-controlled trial. Lancet 372(9633), 127-138 (2008).
47. Dicko A, Mantel C, Thera MA et al. Risk factors for malaria infection and anemia for pregnant women in the Sahel area of Bandiagara, Mali. Acta Trop. 89(1), 17-23 (2003).
48. Cisse B, Sokhna C, Boulanger D et al. Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial. Lancet 367(9511), 659-667 (2006).
49. Massad E, Behrens RH, Burattini MN, Coutinho FA. Modelling the risk of malaria for travelers to areas with stable malaria transmission. Malar. J. 8, 296 (2009).
50. Behrens RH, Carroll B, Beran J et al. The low and declining risk of malaria in travellers to Latin America: is there still an indication for chemoprophylaxis? Malar. J. 6, 114 (2007).
51. Behrens RH, Bisoffi Z, Björkman A et al. Malaria prophylaxis policy for travellers from Europe to the Indidan sub continent. Malar. J. 5, 7 (2006).
52. Pistone T, Schwarzinger M, Chauvin P et al. Reimbursement of malaria chemoprophylaxis for travellers from Europe to sub-Saharan Africa: cost-effectiveness analysis from the perspective of the French national health insurance system. Health Policy 88(2-3), 186-199 (2008).
53. Widmer LL, Blank PR, Van Herck K, Hatz C, Schlagenhauf P. Cost-effectiveness analysis of malaria chemoprophylaxis for travellers to west-Africa. BMC Infect. Dis. 10, 279 (2010).
54. Behrens RH, Carroll B, Hellgren U et al. The incidence of malaria in travellers to South-East Asia: is local malaria transmission a useful risk indicator? Malar. J. 9, 266 (2010).
55. Massad E, Behrens BC, Coutinho FA, Behrens RH. Cost risk benefit analysis to support chemoprophylaxis policy for travellers to malaria endemic countries. Malar. J. 10, 130 (2011).
56. Rolland E, Checchi F, Pinoges L, Balkan S, Guthmann JP, Guerin PJ. Operational response to malaria epidemics: are rapid diagnostic tests cost-effective? Trop. Med. Int. Health 11(4), 398-408 (2006).
57. Reyburn H, Mbatia R, Drakeley C et al. Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study. BMJ 329(7476), 1212 (2004).
58. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. 359(24), 2619-2620 (2008).
59. Dondorp AM, Nosten F, Yi P et al. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361(5), 455-467 (2009).